Investigation of Modifiers of β-Glucocerebrosidase in Cell Models of Parkinson’s Disease
Objective: We firstly aim to identify modifiers of β-glucocerebrosidase (GCase) activity and expression in Parkinson’s disease (PD) relevant cell models. We secondly aim to ascertain…A novel alpha-synuclein gene (SNCA) missense variant in an Austrian familiy with atypical neuropathological features
Objective: To offer clinical, genetic and neuropathological information in a novel alpha-synuclein gene (SNCA) missense variant to further our understanding of synucleinopathies. Background: Around 5–10% of…Utilising multiple murine models to investigate sleep and circadian system dysfunction in PD
Objective: We aimed to investigate the impact of alpha-synuclein aggregation and spreading, and nigrostriatal dopaminergic degeneration on sleep homeostasis and circadian function. Background: Sleep dysfunction…Safety, Target Engagement and Effects of Bosutinib in Dementia with Lewy Bodies
Objective: To investigate the safety, biomarkers effects and determine the lowest effective dose of Bosutinibin Dementia with Lewy Bodies (DLB) Background: The effects of bosutinib,…Development of C-terminal α-Synuclein Vaccine for Treatment and Prevention of Parkinson’s Disease and Other Synucleinopathies
Objective: Prothena is developing active vaccine candidates targeting α-synuclein (α-syn) epitopes shown in clinical and/or preclinical studies to disrupt synuclein pathology. These vaccines, which target…Insights from skin biopsies: α-synuclein real-time quaking-induced conversion (RT-QuIC) in patients with Parkinson’s disease and multiple system atrophy
Objective: To characterize skin alpha-synuclein (α-syn) pathology in synucleinopathies as a potential tool for differential diagnosis. Background: Differential diagnosis of PD and MSA represents a…No evidence for the impact of SNCA rs356219 on Parkinson’s disease progression
Objective: To replicate findings from previous studies reporting an association between the α-synuclein (SNCA) rs356219 genetic variant and progression to key outcomes in Parkinson’s disease…The anti-alpha-synuclein antibody Lu AF82422 was safe and well tolerated in a FIH-SAD study in healthy subjects and patients with PD
Objective: Evaluation of safety, tolerability, pharmacokinetics (PK) and target engagement (TE) in healthy subjects (HS) and patients with Parkinson’s disease (PD) following single ascending doses…Can membrane association of α-synuclein aggregates lead to stress in the astrocytic endoplasmic reticulum?
Objective: To study the association extracellularly added wildtype-WT and A30P/A53T mutant α-synuclein aggregates with the astrocytic membrane and to evaluate the effect of these peptides…The overexpression of a-SYN leads to a differential process of mitophagy in neurons and atrocytes
Objective: To determine the role of the different mitophagy pathways involved in PD, a key question that is still unresolved. We will investigate whether a-synuclein…
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 51
- Next Page »